hERG Channels: From Antitargets to Novel Targets for Cancer Therapy

In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to f...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2017-01, Vol.23 (1), p.3-5
Main Authors: Arcangeli, Annarosa, Becchetti, Andrea
Format: Article
Language:English
Subjects:
Animals
Anticancer properties
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor
Cancer
Cancer therapies
Cardiotoxicity
Ether-A-Go-Go Potassium Channels - antagonists & inhibitors
Ether-A-Go-Go Potassium Channels - metabolism
Humans
Molecular Targeted Therapy
Potassium Channel Blockers - pharmacology
Potassium Channel Blockers - therapeutic use
Potassium channels
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this issue of Clinical Cancer Research, evidence is provided on how to avoid cardiotoxicity when targeting hERG K channel for cancer therapy. hERG regulates different aspects of neoplastic progression. Although its blockade has effective anticancer effects in experimental models, it may lead to fatal arrhythmias in humans. Clin Cancer Res; 23(1); 3-5. ©2016 AACRSee related article by Pointer et al., p. 73.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-16-2322